Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)
Status:
Terminated
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
Treatment protocol to see if people with hepatitis C (HCV) and chronic kidney disease (CKD)
who are treated with Harvoni for 12 weeks have improvements in their kidney disease.
Phase:
N/A
Details
Lead Sponsor:
Massachusetts General Hospital
Treatments:
Ledipasvir Ledipasvir, sofosbuvir drug combination Sofosbuvir